Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06056336 | Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 73 | Guo XufengOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05450029 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer(SILAR) | recruiting | Phase 2 | 51 | Yanhong DengOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05318794 | Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer(SPECTRA) | not yet recruiting | Phase 2 | 20 | Imperial College LondonOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05962502 | Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy | recruiting | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT06014944 | Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody(PMMR/MSS) | not yet recruiting | Phase 2 | 30 | Changhai HospitalOTHER | 0 | Aug 31, 2023 | clinicaltrials |
| NCT06009029 | SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | not yet recruiting | Phase 2 | 96 | Peking University Third HospitalOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT06006650 | Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | recruiting | Phase 2 | 114 | Tang-Du HospitalOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05985707 | KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | not yet recruiting | Phase 2 | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05998122 | Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study | not yet recruiting | Phase 2 | 45 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT04764227 | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) | active not recruiting | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05969847 | Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer(TRACE-LE) | not yet recruiting | Phase 2 | 72 | 池畔OTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970627 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | not yet recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05954897 | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05939661 | A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer(AMBITION) | recruiting | Phase 2 | 45 | Osaka UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05917431 | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | recruiting | Phase 2 | 39 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05909423 | Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer(FLU-IMMUNE) | not yet recruiting | Phase 2 | 21 | Zealand University HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05897138 | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03488667 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | active not recruiting | Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05841134 | Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT05687357 | Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma | recruiting | Phase 2 | 140 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05807984 | Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion | not yet recruiting | Phase 2 | 31 | Xin CaiOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT05794750 | Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）(AK104-IIT-13) | not yet recruiting | Phase 2 | 50 | JIN JINGOTHER | 0 | Apr 6, 2023 | clinicaltrials |
| NCT03544736 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | active not recruiting | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05536102 | The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) | recruiting | Phase 2 | 38 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05757336 | Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer | recruiting | Phase 2 | 50 | Lu Wang, MD, PhDOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05136326 | Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer(CATARTIC) | recruiting | Phase 2 | 21 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05747716 | SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC | not yet recruiting | Phase 2 | 44 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05725200 | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer(EVIDENT) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05732662 | SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC | not yet recruiting | Phase 2 | 25 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 17, 2023 | clinicaltrials |
| NCT04014530 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study(ATAPEMBRO) | recruiting | Phase 1 / Phase 2 | 47 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04304209 | Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 195 | Sun Yat-sen UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04833387 | PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer | active not recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05679583 | Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer | recruiting | Phase 2 | 25 | Yonsei UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05252078 | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients(ALTER-E005) | recruiting | Phase 2 | 30 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05648487 | HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis | not yet recruiting | Phase 2 | 46 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Dec 16, 2022 | clinicaltrials |
| NCT05651672 | Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations | recruiting | Phase 2 | 100 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05300945 | HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 200 | Zhixin CaoOTHER | 0 | Dec 6, 2022 | clinicaltrials |
| NCT05618821 | Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer | recruiting | Phase 2 | 68 | Fujian Medical UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05359393 | A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis(Miracle-1) | not yet recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05563922 | Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma(OP-TNT) | recruiting | Phase 2 | 56 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05171335 | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | enrolling by invitation | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT05524974 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | not yet recruiting | Phase 2 | 203 | Fujian Medical UniversityOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05300269 | SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 73 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Sep 28, 2023source: clinicaltrials